BPC-157 + TB-500 - Blend

BPC-157 + TB-500 – Blend

$320.00

The BPC-157 and TB-500 peptide blend combines two highly researched compounds known for their potential to support tissue repair, regeneration, and inflammation control in preclinical models. BPC-157, derived from a gastric protective protein, has been studied for its angiogenic properties and its role in promoting healing of tendons, ligaments, muscles, and the gastrointestinal tract. TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation, cell migration, and wound healing.

Together, this blend is designed to offer synergistic effects that may accelerate recovery and enhance tissue integrity. It is used in research focused on musculoskeletal injuries, chronic inflammation, and tissue remodeling. This product is intended strictly for laboratory research purposes and is not approved for human consumption.

0% 1 - 4 $320.00
10% 5 - 9 $288.00
20% 10 + $256.00
  • Free shipping on orders over $200
  • Discounts: Calculated in cart.

Description

The BPC-157 and TB-500 peptide blend presents a compelling combination for researchers investigating regenerative medicine and advanced healing processes. Both peptides are well-known in the research community for their ability to modulate inflammation, stimulate tissue repair, and improve vascular function in preclinical models. When combined, they create a powerful dual-acting formula capable of influencing several biological pathways associated with recovery and repair.

BPC-157 is a synthetic peptide fragment derived from the body protection compound found in human gastric juices. It has been shown in rodent studies to accelerate healing in a variety of tissue types, including muscle, tendon, ligament, and even the gut lining. Its mechanism appears to involve upregulation of VEGF (vascular endothelial growth factor), which plays a central role in angiogenesis and microcirculation—both crucial for proper wound healing. BPC-157 has also demonstrated protective effects on the gastrointestinal tract and central nervous system.

TB-500, the synthetic version of Thymosin Beta-4, works primarily by regulating actin polymerization, a vital component of cellular structure and movement. It has been studied for its potential to stimulate cell migration, reduce inflammation, and enhance the repair of skin, muscle, and connective tissues. Studies in animal models have shown its ability to speed up healing in corneal injuries, myocardial infarction, and musculoskeletal damage.

Together, these peptides may support enhanced regeneration, not only by accelerating physical repair but also by modulating immune response and improving tissue oxygenation through new blood vessel formation. Researchers are exploring the blend’s efficacy in models of post-surgical recovery, tendon repair, joint degeneration, and even neural regeneration.

This peptide blend is provided as a lyophilized powder and is intended exclusively for in vitro and animal research. It is not for human use and is sold only for scientific investigation in controlled environments.

Product Data:

  • BPC-157 Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
  • TB-500 Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Lys-Asn-Pro-Thr-Glu-Ser
  • Molecular Formula (BPC-157): C62H98N16O22
  • Molecular Formula (TB-500): C212H350N56O78S
  • Molecular Weight (BPC-157): 1419.54 g/mol
  • Molecular Weight (TB-500): ~4963 g/mol
  • CAS Number (BPC-157): 137525-51-0
  • CAS Number (TB-500): 77591-33-4

Research

Research into the combination of BPC-157 and TB-500 has grown in recent years due to their complementary roles in tissue repair and immune regulation. Both peptides have independently demonstrated promising results in a wide range of animal studies, and their synergistic potential opens new avenues for regenerative science.

BPC-157 has been extensively studied in rodent models where it promotes angiogenesis, reduces pro-inflammatory cytokines, and accelerates wound closure. In tendon and ligament injury models, BPC-157 improved mechanical strength and collagen organization. Its effects on gastrointestinal mucosa have been particularly notable, where it provided significant protection against ulcers and improved intestinal integrity. These outcomes suggest that BPC-157 may influence the nitric oxide pathway and fibroblast activity, contributing to rapid cellular repair.

TB-500, meanwhile, enhances cellular motility by modulating actin polymerization. This property allows for more efficient migration of cells to injured sites, a critical factor in the initial stages of healing. Studies on TB-500 have observed enhanced recovery in models of corneal damage, myocardial ischemia, and skeletal muscle trauma. In particular, it has been shown to support revascularization and reduce inflammation in cardiac and muscle tissues.

When studied together, the combination has shown amplified effects in animal models. One reason for this may be the distinct yet intersecting mechanisms of action—while BPC-157 boosts blood flow and healing factors at injury sites, TB-500 facilitates the actual repair processes through cellular movement and cytoskeletal reorganization.

Experimental models investigating severe tendon and ligament injuries have demonstrated faster and more complete recovery when both peptides are administered concurrently. There is also interest in their potential to support recovery after surgeries and to counteract degenerative joint conditions. The anti-inflammatory and neuroprotective aspects of this combination are under preliminary exploration, particularly in studies examining neural damage and oxidative stress.

While these findings are promising, it's essential to note that all results are limited to laboratory and animal research. Neither compound has been approved by regulatory agencies for medical use in humans. Further studies, including toxicological profiles and long-term safety assessments, are required.

This product is for laboratory research only and is not intended for diagnostic or therapeutic use in humans or animals.

References:

  1. Su, L., Kong, X., Loo, S., Gao, Y., Liu, B., Su, X., Dalan, R., Ma, J., & Ye, L. (2022). Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells. Stem cell research & therapy, 13(1), 13. https://doi.org/10.1186/s13287-021-02687-x.
  2. Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., … Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533.

Related products

Scroll to Top
0